Overview
A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Status:
Completed
Completed
Trial end date:
2013-11-01
2013-11-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg. GLA5PR GLARS tablet 150mg is a New Formulation which is made by GL Pharm Tech. GLARS(Geometrically Long Absorption Regulated System) is New Solution to Sustained Absorption by Extending the Absorption Site. To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
GL Pharm Tech CorporationTreatments:
Pregabalin
Criteria
Inclusion Criteria:- 20~45 years old, Healthy Adult Male Subject
- 17.5~30.5kg/m2(BMI) and ≥ 45kg
Exclusion Criteria:
- SBP ≥ 140mmHg or DBP ≥ 90mmHg